Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome
04.12.2012Tioga Pharmaceuticals, Inc. today announced the closing of a $10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $8 million in the round ...more
Tioga's lead product is asimadoline, a proprietary,
peripherally restricted small molecule kappa opioid agonist,
originally discovered by Merck KGaA of Darmstadt, Germany.
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
IBS is a common condition that is found in high prevalence throughout the world. Affected patients
experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern ...more